IRadimed Corporation — Q3 2014 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014. The unaudited filing covers a medical-device company selling MRI-compatible IV infusion pumps, disposable tubing sets, and services. IRadimed completed its IPO in July 2014.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $3.81 million | $2.48 million | $12.07 million | $7.88 million |
| Gross profit | $2.85 million | $1.81 million | $9.58 million | $5.98 million |
| Gross margin | 74.8% | 73.0% | 79.4% | 75.8% |
| Operating income | $406,000 | $356,000 | $2.84 million | $2.06 million |
| Net income | $237,000 | $261,000 | $1.78 million | $1.46 million |
| Diluted earnings per share | $0.02 | $0.03 | $0.18 | $0.17 |
- Q3 revenue rose 53.7% year over year, while net income declined. Q3 operating expenses increased to $2.45 million from $1.45 million, including higher general and administrative and sales and marketing costs.
- Nine-month revenue increased 53.1%. U.S. revenue rose to $10.20 million from $5.49 million; international revenue declined to $1.87 million from $2.39 million. Pump sales were 404 units versus 289 in the comparable period.
- Nine-month operating cash flow was $3.49 million, compared with $707,000. Investing activities used $274,000; financing provided $12.44 million, principally from the IPO.
- At September 30, cash and equivalents were $18.11 million, working capital was $19.1 million, and stockholders’ equity was $20.15 million. The company reported no outstanding officer note and had terminated its uncommitted $100,000 credit facility; no other material debt is reported.
- The IPO sold 2,318,400 shares at $6.25 per share, generating approximately $12.4 million in net proceeds after underwriting discounts and expenses.
Material changes and management outlook
- FDA warning and U.S. distribution halt: Following an April 2014 inspection and a September 2 warning letter, the FDA stated that software changes to the MRidium 3860 and 3850 required new 510(k) submissions and that the 3860+ required separate clearance. IRadimed disputed the FDA’s assessment, but complied with the request and stopped U.S. sales and distribution of the identified pumps. Management said the halt significantly affected Q3 revenue and net income and expected it to continue harming results until domestic shipments could resume.
- The company submitted responses to the FDA on September 4 and September 17 and said it was working to resolve the matter. It gave no specific timetable or quantified forecast for renewed distribution. It warned that the FDA could require additional corrective actions, impose restrictions or penalties, or pursue other regulatory remedies.
- Management expected 2014 operating expenses to increase due to headcount, capital spending, the new headquarters, FDA response and legal costs, and public-company expenses. It also expected inventory to increase while building pump systems in anticipation of FDA clearance.
- Management believed cash and expected operating cash generation would cover operating requirements for at least 12 months and did not anticipate needing additional capital, though it could seek financing if necessary.
- The company reported one operating segment and estimated approximately 2,175 installed systems globally. Its business is substantially dependent on its MRI-compatible pump products.
Risks, contingencies, and unusual items
- A shareholder class action filed in September alleges securities-law violations concerning disclosures about FDA compliance. The company disputes the allegations, intends to defend itself, and recorded no loss because it considered a loss neither probable nor estimable.
- A separate German trademark dispute seeks to restrict use of the IRADIMED name in Europe and unspecified damages. No loss was accrued because management considered it neither probable nor estimable.
- The company leases its manufacturing and headquarters facility from an entity controlled by its CEO. Base rent is $32,583 per month, subject to annual CPI adjustments; reported remaining non-cancelable lease commitments totaled $1.82 million.
- Key operational risks include reliance on a single product, FDA clearance and compliance, single-source suppliers, a single Florida manufacturing facility, international distributors, and dependence on the CEO-founder. The filing also identifies customer concentration, product-liability, foreign-exchange, and public-company compliance risks.
- The nine-month effective tax rate rose to 37.5% from 30.4%, primarily due to higher state taxes and expiration of the research and development tax credit. Q3 effective tax rate was 40.3%, versus 30.4%.
- Management said disclosure controls and procedures were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Current FDA status, required submissions or corrective actions, and whether U.S. sales and distribution have resumed.
- Revenue, margins, cash flow, and inventory trends while domestic shipments are restricted; the filing gives no clear quantified estimate of the stop-ship’s future impact.
- Developments and potential financial exposure in the securities class action and German trademark litigation.
- Terms and ongoing cost of the related-party facility lease, and progress toward reducing reliance on the single facility and key suppliers.
- Potential dilution from outstanding options and the 201,600 underwriter warrants, exercisable at $8.13 per share beginning July 21, 2015.